Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 279-290

  Farnier, Michel ^a   Chen, Erluo ^b   Johnson Levonas, Amy O ^b   McCrary Sisk, Christine ^b   Mitchel, Yale B ^b  

^a Point Medical   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

apoB; LDL C; non HDL C

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

APOB; LDL-C; NON-HDL-C;

ADULT; AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; LINEAR MODELS; MIDDLE AGED; NIACIN; RISK FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900019318     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S58694     Document Type: Article

References (29)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
2. Stone NJ, Robinson J, Lichtenstein AH, etal. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. Epub November 7, 2013.
3. Brunzell JD, Davidson M, Furberg CD, etal. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.
4. Davidson MH, Ballantyne CM, Jacobson TA, etal. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338-367.
5. Genest J, McPherson R, Frohlich J, etal. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
6. Catapano AL, Reiner Ž, De Backer G, etal. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:1-44.
7. Boekholdt SM, Arsenault BJ, Mora S, etal. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302-1309.
8. Ingelsson E, Schaefer EJ, Contois JH, etal. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776-785.
9. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363-1368.
10. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112: 3375-3383.
11. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316-322.
12. Sniderman AD, Williams K, Contois JH, etal. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337-345.
13. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005;96:3K-13K.
14. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko R, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737-743.
15. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
16. Brown BG, Zhao X-Q, Chait A, etal. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
18. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365: 2255-2267.
19. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291.
20. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88:265-269.
21. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008;52: 626-632.
22. Charlton-Menys V, Betteridge DJ, Colhoun H, etal. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem. 2009;55:473-480.
23. Idris I, Tate H, Ahmad A, McCormack T. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: post-hoc analyses from the UK InPractice study. J Clin Lipidol. 2011;5:316-323.
24. Grundy SM, Vega GL, Tomassini JE, Tershakovec AM. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009;104:548-553.
25. Farnier M, Taggart W, Dong Q, Lin J, Shah A, Brudi P. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of LDL and non-HDL cholesterol with apolipoprotein B in mixed dyslipidemic patients. J Clin Lipidol. 2011;5:179-187.
26. Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P. Effects of Ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis. 2013;229:415-422.
27. Gleim G, Ballantyne CM, Liu N, etal. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16:90-97.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
29. Maccubbin D, Bays HE, Olsson AG, etal. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959-1970.